EXPERIENCE OF THE USE OF CETUXIMAB IN THE TREATMENT OF PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE LARYNX
We evaluated the effectiveness of the combination of cetuximab/cisplatin and 5-ftoruracil in the treatment of 20 patients with laryngeal I-III stage of squamous cell carcinoma aged 55-68 years. The data were compared with the results of treatment of patients who have received a similar pattern of cisplatin, 5- ftoruracil, but without cetuximab. WBC and immature granulocytes – IG, neutrophils – Ne, lymphocytes – Ly, monocytes – Mo, C-reactive protein – CRP, lactate dehydrogenase – LDH, creatinine were studied number. According to the data aquired combination of cetuximab/cisplatin and 5-fluorouracil improves the efficiency of the treatment of patients with laryngeal cancer. Cetuximab in combination with cisplatin and 5-fluorouracil has the minimum toxic effects.